EDUCATION and EMPLOYMENT
2019-Present Assistant Professor, Department of Basic Medical Sciences,Tsinghua University, Beijing, China
2019-Present Investigator, THU-PKU Center for Life Sciences,Beijing, China
2016-2019 Research Fellow, Department of Cancer Immunology and Virology Dana-Farber Cancer Institute, Boston, MA.Harvard Medical School, Boston, MA.
2010-2016 Doctorate of Cancer Biology,MD Anderson Cancer Center, Houston, TX.Advisor: Xin Lin, Ph.D.
2007-2009 Bachelor of Medicine, School of Biotechnology,Southern Medical University, Guangzhou, China.
HONORS and FELLOWSHIPS
2019/7 Bayer Investigator Award
2019/5 One Thousand Talent Program Award
2017/4 Robertson Postdoctoral fellowship, Cancer Research Institute
2014/11 Andrew Sowell-Wade Huggins Scholarship, MD Anderson Cancer Center
2014/3 Cancer Biology Program Award, MD Anderson Cancer Center
2013/3 Cancer Biology Program Poster Award, MD Anderson Cancer Center
RESEARCH SUMMARY
Dr. Deng Pan’s research focuses on understanding cancer immune evasion mechanisms and identification of novel cancer immunotherapy target. Through cutting-edge functional genomic approaches and by establishing various in vitro and in vivo screening assays, we investigate the pathways employed by tumor cells to thwart elimination by different types of immune cells, such as CD8+ T cells, NK cells, and macrophages (Wu et al., Cell Metabolism, 2023; Pan et al.,Science, 2018; Ito et al., Cancer Discovery 2023). The lab also develops functional screens invarious types of tumor-infiltrating immune cells, including major lymphoid and myeloid lineages. Through genetic perturbations in both tumor and immune cells, the lab’s goal is to gaina comprehensive understanding of immune evasion mechanisms, paving the way for the development of novel and effective strategies in cancer immunotherapy.Curriculum Vitae: Deng Pan (July, 2024)
PUBLICATIONS
As Principal Investigator
Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, Yu X, Xiong K, Luo C, Zhu J, Wang F# , Zeng Z# ,Pan D# . Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to Tcell-mediated bystander killing via TNFa. Cell Metabolism, 2023 Sep 5;35(9):1580-1596.e9. doi:10.1016/j.cmet.2023.07.001. (# denotes corresponding authors)
Meng J, Jiang YZ, Zhao S, Tao Y, Zhang T, Wang X, Zhang Y, Sun K, Yuan M, Chen J, Wei Y,Lan X, Chen M, David CJ, Chang Z, Guo X, Pan D, Chen M, Shao ZM, Kang Y, Zheng H.Tumor-derived Jagged1 promotes cancer progression through immune evasion. Cell Rep. 2022 Mar 8; 38(10):110492
As Postdoc or graduate student
Ito Y*, Pan D*, Zhang W, Zhang X, Juan TY, Pyrdol JW, Kyrysyuk O, Doench JG, Liu XS,Wucherpfennig KW. Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines. Cancer Discov. 2023 May 4;13(5):1186-1209. doi: 10.1158/2159-8290.CD-22-1125. (* Denotes equal contribution)
Shi S, Gu S, Han T, Zhang W, Huang L, Li Z, Pan D, Fu J, Ge J, Brown M, Zhang P, Jiang P,Wucherpfennig KW, Liu XS. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PDL1 in Human Tumors. Clin Cancer Res. 2020 Nov 15;26(22):5990-6002.
Ferrari de Andrade L, Kumar S, Luoma AM, Ito Y, Alves da Silva PH, Pan D, Pyrdol JW, YoonCH, Wucherpfennig KW. Inhibition of MICA and MICB Shedding Elicits NK-Cell-MediatedImmunity against Tumors Resistant to Cytotoxic T Cells Cancer Immunol Res. 2020 Jun;8(6):769-780.
De Andrade LF, Lu Y, Luoma A, Ito Y, Pan D, Pyrdol JW, Yoon CH, Yuan GC, Wucherpfennig KW.Discovery of specialized NK cell populations infiltrating human melanoma metastasis. JCI Insight. 2019 Dec 5;4(23):e133103.
Pan D*, Kobayashi A*, Jiang P*, Andrade LF, Tay RE, Luoma A, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan G, Doench J, Brown M, Liu XL, and Wucherpfennig KW. A Major Chromatin Regulator Determines Resistance of Tumor cells to T cell Mediated Killing. Science, 2018 Jan 4;pii:eaao1710 doi: 10.1126/science.aao1710. (* Denotes equal contribution)
(Highlighted paper for postdoctoral work)
Jiang P*, Gu S*, Pan D*, Fu J, Li Z, Bu X, Li B, Liu JS, Freeman G, Brown M, Wucherpfennig KW and Liu XL. Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 2018 Oct;24(10):1550-1558. (* Denotes equal contribution)
(Highlighted paper for postdoctoral work)
Andrade LF, Tay RE, Pan D, Luoma A, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi S, Dranoff G and Wucherpfennig KW. Antibody-Mediated Blockade of MICA/B Shedding Promotes NK Cell-Driven Tumor Immunity. Science 2018, Mar 30; Vol 359, Issue 6383, pp. 1537-1542) DOI: 10.1126/science.aao0505Curriculum Vitae: Deng Pan (July, 2024)
Zhang S, Pan D, Jia XM, Lin X and Zhao X. The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-kB activation and cell survival. Protein Cell. 2017 Nov;8(11):856-860.
Wang A, Ding X, Demarque M, Liu X, Pan D, Xin H, Zhong B, Wang X, Dejean A, Jin W and Dong C. Ubc9 Is Required for Positive Selection and Late-Stage Maturation of Thymocytes. J Immunol. 2017 May 1; 198(9): 3461-3470.
Pan D, Jiang C, Ma Z, Blonska M, You MJ and Lin X. The role of MALT1 in EGFR induced NFkappaB activation and EGFR associated lung cancer progression. Oncogene. 2016 Feb 18;35(7):919-28.
Pan D*, Zhu Y*, Zhou Z, Wang T, You H, Jiang C and Lin X. CARMA3-BCL10-MALT1 -mediated NF-kB activation contributes to HRE2-assocaited tumor malignancy in breast cancer.Mol Cancer Res. 2016 Jan ;14(1):93-102. (* denotes equal contribution)
Wang T, Pan D, Zhou Z, You Y, Jiang C, Zhao X and Lin X. Dectin-3 Deficiency Promotes Colitis Development due to Impaired Antifungal Innate Immune Responses in the Gut. PLoS Pathog; 2016 Jun 9;12(6): e1005662.
Pan D and Lin X. EGFR-activated NF-kappaB Signaling and Its Role in EGFR-associatedm Tumors. Cancer J. 2013 Nov-Dec;19(6):461-7.
Wang A, Pan D, Lee Y, Gustavo M, Feng XF, and Dong C. Cutting Edge: Smad2 and Smad4 regulate TGFbeta-mediated Il9 gene expression via EZH2 displacement. J Immunol. 2013 Nov 15; 191(10):4908-12.
Pan D, Hu J, Ma Q, Pan W and Li M. Diversity and prevalence of the C-terminal region of Plasmodium falciparum Merozoite Surface Protein 1 in China. Acta Trop. 2010 Dec; 116(3):200-5.
GRANTS
Active fundin
Principle Investigator, Mechanistic study of bystander T cell-mediated killing of tumor cells,NSFC, 2020-2024
Principle Investigator, Mechanistic studies of tumor associated macrophage-mediated regulation of the tumor microenvironment, 2023-2026
Principle Investigator, Bayer Healthcare LLC supported project, 2020-2023
Principle Investigator, Boehringer Ingelheim supported project, 2023-2025
Principle Investigator, Beijing Cooperation Innovation Research Institute, 2023-2024
Completed funding
Principle Investigator, Cancer Research Institute fellowship, 2017-2019Curriculum Vitae: Deng Pan (July, 2024)
Principle Investigator, Systematic discovery of resistance mechanisms to immunotherapy and
immunotherapy targets, One Thousand Talent Program,2019-2022
TALKS and PRESENTATIONS
2021/7 Invited talk at Beijing Cancer Hospital “Systematic discovery of novel target for tumor immunotherapy”. Beijing, China
2020/6 Invited talk at 301 Hospital, “High throughput approach for identification of immunotherapy target”. Beijing, China
2018/10 Invited talk at Tsinghua-Nature Conference on Inflammation and Cancer. Title: Tumor Intrinsic resistance mechanisms to T cell-mediated killing.
2018/9 Poster presentation, CRI-CIMT-EATI-AACR Fourth International Cancer Immunotherapy Conference
2018/2 Invited Talk, Functional genomic consortium, Broad Institute, Cambridge, MA. Title: “Systematic discovery of immune modulators in tumor cells”.
2018/1 Invited talk at Genomic perturbation platform, Broad Institute, Cambridge, MA. Title: “Systematic discovery of immune modulators in tumor cells”.
2013/4 Poster presentation, Annual meeting of AACR, Washington, D.C. Abstract 3389: Nuclear accumulation of c-Rel transcription factor is correlated with the proteasome inhibitor resistance in mantle cell lymphoma.
2012/11 Center of Inflammation and Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX. Title: The role of MALT1 in tumor progression.
2012/4 The 26th Society of Chinese Biosciences in America (SCBA) Texas Chapter Symposium, Houston, TX. Title: The role of MALT1 in tumor progression.
TEACHING
Medical Cell Biology (Undergraduate level) 15hours/year
Immunology (Undergraduate level) 8 hours/year
Advances in Tumor Biology (Graduate level) 16 hours/year
Critical thinking in Life Science Research (Graduate level) 12 hours/year
MENTORING
2019-2024 Jiahui Li, PhD Program in basic medical sciences, Tsinghua University
2019-2023 Lijian Wu, PhD Program in basic medical sciences, Tsinghua University
2019-present Hefei Wang, CLS postdoctoral fellow program, Tsinghua University
2019-present Jie Zhao, CLS postdoctoral fellow program, Tsinghua University
2019-2020 Kun Zhao, Undergraduate internship program, Tsinghua University
2020-present Xindi Zhou, PhD Program in basic medical sciences, Tsinghua University
2020-present Youxue Lu, PhD Program in basic medical sciences, Tsinghua University
2020-present Yilan Wu, MD program, Tsinghua University
2020-2021 Ke Xiong, Undergraduate internship program, Tsinghua University
2020-present Fangting Zhao, Undergraduate internship program, Tsinghua University
2021-present Changhe Li, PhD Program in basic medical sciences, Tsinghua University
2021-present Hao Gong, PhD Program in basic medical sciences, Tsinghua University
2022-present Xuerong Yu, PhD Program in basic medical sciences, Tsinghua University
2022-present Fangting Zhao, PhD Program in basic medical sciences, Tsinghua University
2022-present Xi Zhao, PhD Program in basic medical sciences, Tsinghua UniversityCurriculum Vitae: Deng Pan (July, 2024)
2022-present Jieyu Chu, PTN Graduate Program, Peking University
2022-present Kaiyang Tang, PhD Program in basic medical sciences, Tsinghua University
INVENTIONS
1. Patent # DFS-190.6 submitted by DFCI
“Methods for sensitizing cancer cells to T cell-mediated killing by modulating biomarkers” Inventors: Deng Pan and Kai W. Wucherpfennig
